Table 1.

Theoretical assessment of progenitor protection—nuclP140K versus mitoP140K

Drug treatmentNo. of progenitors protected based on normalized P140K activity
NuclP140K *MitoP140K
6BG/BCNU (μmol/L)
    2018 ± 248 ± 2
    4012 ± 216 ± 1
    804 ± 1ND
6BG/TMZ (μmol/L)
    10022 ± 11128 ± 3
    20014 ± 356 ± 2
    40012 ± 332 ± 2
  • Abbreviation: ND, none detected.

  • * NuclP140K activity was set at 100%. Because mitoP140K activity was 4-fold lower, the number of colony-forming units protected in the mitoP140K groups was multiplied by 4.